AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The GEMINI-PeriOp GC study, officially titled ‘A Master Protocol of an Open-Label, Multi-Drug, Multi-Center, Phase II Platform Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma,’ aims to assess the safety and effectiveness of new drug combinations in treating locally advanced resectable gastroesophageal adenocarcinoma. This study is significant as it explores innovative treatment options for a challenging cancer type.
The interventions being tested include novel drugs such as AZD0901, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU), and FLOT Chemotherapy. These treatments are designed to be administered both before and after surgery to improve patient outcomes.
The study follows a non-randomized, parallel intervention model without masking, focusing primarily on treatment. Participants are divided into three sub-studies, each testing different drug combinations to evaluate their effectiveness and safety.
The study began on July 17, 2025, with its primary completion and estimated completion dates yet to be announced. The most recent update was submitted on August 20, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical study update could impact AstraZeneca’s stock performance positively by showcasing its commitment to innovative cancer treatments. Investors may view this as a strategic move to strengthen its oncology portfolio. The involvement of Parexel as a collaborator highlights the study’s robust design and potential industry impact.
The study is currently recruiting, with further details available on the ClinicalTrials portal.